Insider Selling: Disc Medicine (NASDAQ:IRON) CEO Sells $2,473,680.00 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) CEO John Quisel sold 33,000 shares of the firm’s stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $74.96, for a total transaction of $2,473,680.00. Following the sale, the chief executive officer directly owned 226,064 shares of the company’s stock, valued at $16,945,757.44. The trade was a 12.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Disc Medicine Trading Down 3.4%

IRON opened at $73.47 on Friday. The stock has a market capitalization of $2.80 billion, a PE ratio of -11.10 and a beta of 0.97. The firm’s fifty day moving average price is $71.04 and its 200 day moving average price is $69.88. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.00 and a quick ratio of 24.00. Disc Medicine, Inc. has a 12-month low of $40.00 and a 12-month high of $99.50.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). As a group, research analysts expect that Disc Medicine, Inc. will post -6.74 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a research note on Monday, April 20th. Wedbush restated an “outperform” rating and set a $88.00 price objective on shares of Disc Medicine in a research note on Wednesday, June 10th. Wall Street Zen raised Disc Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Finally, Morgan Stanley lifted their target price on Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a research report on Monday, June 15th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Disc Medicine has a consensus rating of “Moderate Buy” and an average price target of $104.44.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. RA Capital Management L.P. grew its position in shares of Disc Medicine by 25.3% during the 4th quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock valued at $156,925,000 after buying an additional 399,026 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Disc Medicine by 22.1% in the fourth quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company’s stock worth $140,371,000 after acquiring an additional 319,621 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Disc Medicine by 28.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company’s stock worth $134,839,000 after acquiring an additional 371,576 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Disc Medicine by 110.0% in the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock valued at $125,557,000 after acquiring an additional 828,248 shares during the period. Finally, Wellington Management Group LLP boosted its stake in Disc Medicine by 7.7% in the fourth quarter. Wellington Management Group LLP now owns 1,518,274 shares of the company’s stock valued at $120,566,000 after acquiring an additional 108,197 shares during the period. 83.70% of the stock is currently owned by institutional investors.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.